LMLuisa Morelli

Luisa Morelli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luisa Morelli has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Macpherson

    Department of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland; 4Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland

    1 shared publication
  • Annika Bestehorn

    Max Perutz Labs, Vienna Biocenter Campus (VBC)

    1 shared publication
  • Arthur Mauduit

    IRSD, University of Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France; 2Gastroenterology, Hepatology, Nutrition, Diabetology and Hereditary Metabolic Diseases Unit, Hôpital des Enfants, CHU de Toulouse, F-31300 Toulouse, France

    1 shared publication
  • Emmanuel Mas

    IRSD, University of Toulouse, INSERM, INRAE, ENVT, UPS, Toulouse, France; 2Gastroenterology, Hepatology, Nutrition, Diabetology and Hereditary Metabolic Diseases Unit, Hôpital des Enfants, CHU de Toulouse, F-31300 Toulouse, France

    1 shared publication
  • Floriane Cherrier

    Department of Visceral Surgery and Medicine, Bern University Hospital, Bern, Switzerland; 4Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland

    1 shared publication
  • Frédérick Barreau

    Institut de Recherche en Santé Digestive (IRSD),Université de Toulouse, INSERMUnité 1220, INRAE, ENVT, UPS, Purpan Hospital, Toulouse, France

    1 shared publication

Latest Publications

  • Open Access

    Colitis-primed circulating T cells drive small intestinal barrier function through Nod2, microbiota and myosin light chain kinase-dependent mechanisms

    by Arthur Mauduit, Talal Nabhani, Luisa Morelli, Floriane Cherrier, Rosemary Abdoul Ahad, Nidal Nabhani, Gurminder Singh, Maryline Roy, Gilles Dietrich, Jerrold R. Turner, et al.

    Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are characterized by intestinal inflammation and barrier dysfunction. While disruption of the intestinal barrier contributes to the pathogenesis of IBD, yet how colonic inflammation alters small intestinal homeostasis remains poorly defined. Here, we demonstrate that three models of colitis, including 2,4,6-Trinitrobenzenesulfonic acid (TNBS), Dextran Sulfate Sodium (DSS), and oxazolone, induce paracellular barrier dysfunction in the small intestine, with model-specific immune profiles. Th1/Th17-skewed responses (TNBS and DSS) were associated with microbiota-dependent upregulation of myosin light chain kinase (MLCK), RORγt⁺ CD4⁺ T cell expansion, and elevated expression of Nod2, which was not observed under Th2-dominant (oxazolone) conditions. Inhibition of MLCK restored barrier function and suppressed inflammation in a CD4⁺ T cell–dependent manner. Using Nod2-deficient and 2939insC mutant mice, we showed Nod2 as a critical regulator of small intestinal permeability during colitis. Bone marrow chimeras revealed compartment-specific roles of Nod2, with non-hematopoietic Nod2 sufficient to preserve epithelial integrity, while hematopoietic Nod2 expression is required to limit cytokine-mediated inflammation. Moreover, MLCK inhibition ameliorated intestinal lesions only in mice with Nod2 deficiency in the hematopoietic compartment. Finally, microbiota transfer experiments ruled out a causal role for dysbiosis in driving small intestinal permeability defects in Nod2-deficient mice. These findings uncover a Nod2–MLCK–CD4⁺ T cell axis linking colonic inflammation to small intestinal barrier dysfunction and highlight distinct immune–epithelial–microbial mechanisms shaping intestinal homeostasis during colitis. Graphical Circulating RORγt⁺ Foxp3⁻ CD4⁺ T cells from mice with TNBS- or DSS-induced colitis increase small intestinal permeability by promoting cytokine secretion that enhances MLCK activity. This effect is attenuated by Nod2 activation. Specifically, Nod2 expression in hematopoietic cells reduces cytokine secretion and permeability, while activation of Nod2 in non-hematopoietic cells alone is sufficient to prevent increased permeability by directly regulating MLCK activity, independently of cytokine influence. Moreover, the absence of Nod2 is associated with inflammatory lesions in the small intestine of TNBS-treated mice.

  • Open Access

    Nonredundancy of IL-1α and IL-1β is defined by distinct regulation of tissues orchestrating resistance versus tolerance to infection

    by Kevin Eislmayr, Annika Bestehorn, Luisa Morelli, Martina Borroni, Lieselotte Vande Walle, Mohamed Lamkanfi, Pavel Kovarik

    Interleukin-1α (IL-1α) and IL-1β are inflammatory cytokines with important roles in health and disease. They trigger the same receptor and elicit comparable cellular responses but, for poorly understood reasons, are not redundant in vivo. Here, we decoupled IL-1α and IL-1β functions that drive protective responses against invasive infection with group A Streptococcus . IL-1β was essential for pathogen clearance, hence resistance to infection, by inducing granulocyte colony-stimulating factor at the infection site and establishing emergency granulopoiesis. In contrast, IL-1α governed reprogramming of liver metabolic pathways associated with tolerance to infection. The IL-1α−dominated hepatic regulation corresponded to high IL-1α levels in the liver during infection. Conversely, IL-1β was critical for the regulation of the spleen transcriptome, which correlated with ample IL-1β expression in this tissue. The results identify distinct and organ-specific roles of IL-1α versus IL-1β and implicate spatial restriction of their expression and bioavailability during infection as the underlying mechanism.